Advantages and limits of intravenous thrombolysis.
De Biase
A M
AM
Centro A. de Gasperis, Ospedale Niguarda Cá granda, Milano, Italy.
Mauri
F
F
Rovelli
F
F
D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D013300:Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase